CorTec accepted into FDA Total Product Life Cycle Advisory Program — third patient implanted at Harborview
Summary
CorTec's Brain Interchange BCI was accepted into the FDA Total Product Life Cycle (TAP) Advisory Program in April 2026, providing the German company with early and frequent FDA engagement throughout their device development lifecycle — a program available to fewer than 50 medical device companies globally. Simultaneously, CorTec implanted their third patient at Harborview Medical Center in Seattle as part of their NIH-funded stroke rehabilitation IDE trial, demonstrating continued clinical momentum alongside the April 9 FDA Breakthrough Device Designation.
Why it matters
FDA TAP acceptance gives CorTec structured interaction with FDA reviewers across the full development lifecycle — from design controls through clinical data to submission — reducing the uncertainty that typically accompanies novel device regulatory submissions. Combined with Breakthrough Device Designation, 500-day stability data, and now a third patient, CorTec has achieved more US regulatory milestones in April 2026 than most BCI companies achieve in a year.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial